A new rapid-genomics pilot could shorten a 26-day diagnostic process to hours. Birmingham’s more important role is testing whether that speed can work across the full patient pathway.
IMS Solutions gives the region a stake in hormone diagnostics. Its commercial test will be whether strong clinical evidence can fit real laboratory and patient pathways.
